Company Lexagene Holdings Inc Toronto S.E.
Equities
WEY
CA52886L1031
Biotechnology & Medical Research
Business Summary
Sales per Business
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Genetic Analyzer
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +21.70% |
Sales per region
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +21.70% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jack Regan
CEO | Chief Executive Officer | - | 25/04/07 |
Jeffrey Mitchell
DFI | Director of Finance/CFO | - | 28/02/18 |
Steven Armstrong
COO | Chief Operating Officer | - | 23/03/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph P. Caruso
BRD | Director/Board Member | 65 | 17/06/18 |
Jack Regan
CEO | Chief Executive Officer | - | 25/04/07 |
Tom Slezak
BRD | Director/Board Member | - | 11/10/16 |
Jane Sykes
BRD | Director/Board Member | - | 14/11/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 140,740,255 | 115,621,362 ( 82.15 %) | 0 | 82.15 % |
Company contact information
Lexagene Holdings, Inc.
500 Cummings Center Suite 4550
01915, Beverly
+800 215 1824
http://www.lexagene.comSector
1st Jan change | Capi. | |
---|---|---|
-44.08% | 7.63B | |
+8.98% | 3.61B | |
+3.94% | 2.36B | |
-24.94% | 1.86B | |
-17.38% | 1.74B | |
+4.89% | 913M | |
+21.75% | 763M | |
-11.57% | 678M | |
-30.82% | 500M |